Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JIB-04 (NSC 693627) 是一种 Jumonji 组蛋白去甲基酶广谱抑制剂,能抑制 JARID1A、JMJD2E、JMJD3、JMJD2A、JMJD2B、JMJD2C 和 JMJD2D 的活性,其IC50值分别为 230、340、855、445、435、1100 和 290 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 183 | 现货 | ||
2 mg | ¥ 255 | 现货 | ||
5 mg | ¥ 396 | 现货 | ||
10 mg | ¥ 567 | 现货 | ||
25 mg | ¥ 963 | 现货 | ||
50 mg | ¥ 1,490 | 现货 | ||
100 mg | ¥ 2,380 | 现货 | ||
200 mg | ¥ 3,530 | 现货 | ||
500 mg | ¥ 5,650 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 519 | 现货 |
产品描述 | JIB-04 (NSC 693627) is a pan-selective Jumonji histone demethylase inhibitor. |
靶点活性 | JARID1A:230 nM, JMJD2B:435 nM, JMJD2E:340 nM, JMJD2D:290 nM, JMJD2A:445 nM |
体外活性 | 在H358和A549小鼠异种移植模型中,JIB-04抑制Jumonji组蛋白脱甲基酶的活性,抑制肿瘤细胞生长. |
体内活性 | 在肺癌和前列腺癌细胞系中(IC50=10 nM),JIB-04下调增殖基因,阻断细胞生长。 |
细胞实验 | For cell viability assays, cells are plated at 1500-3000 cells/well in 96 well plates and treated the next day with increasing doses of compound over 4 days and their viability assessed by standard MTS assays using Promega’s Cell Titer or Cell Titer-Glo reagents according to the manufacturer’s protocols. Absorbance at 490 nm and 650 nm or luminescence is measured by a Spectra Max or a FlouroStar Omega plate reader. Data are normalized to the untreated controls (100% viability). Each cell line is tested in 2-5 independent assays, each containing 4-8 replicates. IC50 values are calculated using DIVISA, a high-throughput software, developed in hous, for storing and analyzing drug sensitivity assays. Dose-response curves are plotted using a non-linear regression model and IC50s are determined from the fitted curves. The average IC50 derived from 2-5 independent assays, each containing 4-8 replicates is reported. (Only for Reference) |
别名 | JIB 04, NSC 693627, 5-氯-2(1H)-吡啶酮 (2E)-(苯基-2-吡啶基亚甲基)腙 |
分子量 | 308.76 |
分子式 | C17H13ClN4 |
CAS No. | 199596-05-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30.9 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.2388 mL | 16.1938 mL | 32.3876 mL | 80.969 mL |
5 mM | 0.6478 mL | 3.2388 mL | 6.4775 mL | 16.1938 mL | |
10 mM | 0.3239 mL | 1.6194 mL | 3.2388 mL | 8.0969 mL | |
20 mM | 0.1619 mL | 0.8097 mL | 1.6194 mL | 4.0485 mL | |
50 mM | 0.0648 mL | 0.3239 mL | 0.6478 mL | 1.6194 mL | |
100 mM | 0.0324 mL | 0.1619 mL | 0.3239 mL | 0.8097 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
JIB-04 199596-05-9 Apoptosis Chromatin/Epigenetic Histone Demethylase Histone Methyltransferase Inhibitor JIB 04 NSC693627 NSC-693627 inhibit NSC 693627 5-氯-2(1H)-吡啶酮 (2E)-(苯基-2-吡啶基亚甲基)腙 JIB04 inhibitor